Why now

The June 26 hook is a 10-year milestone, not a breaking clinical result. That actually makes the brief more strategic: it shows the kind of advanced-care infrastructure VV should treat as a breakthrough. Nepal's first BMT center is still described as the only one in the country a decade later, while Binaytara is using the anniversary to point toward a second center. The now is about capacity, not novelty.

Why now

This can be stronger than the seed suggests because the primary Nature Medicine paper is available and the topic sits directly in VV's longevity plus cancer lane. The news peg is not simply 'young people are aging faster.' It is that biological age gap is being proposed as a measurable risk signal associated with early-onset solid cancers, which connects early cancer incidence, prevention, biomarkers, and the limits of causality in one story.

Why now

Although the approval was earlier in June, this is still worth enriching because it is a real regulatory milestone in an aggressive cancer with poor options after platinum therapy. The better why-now is not 'Europe approved a drug.' It is that Amgen's DLL3-targeting T-cell engager moved into a defined EU post-platinum extensive-stage small cell lung cancer setting, backed by Phase 3 DeLLphi-304 survival data, and should now be tracked for access, toxicity management, and real-world uptake.

Why now

This is one of the cleanest regulatory items in the batch because FDA posted a June 24 approval for Trodelvy in two first-line adult TNBC indications. The why-now is immediate patient relevance in an aggressive subtype: an antibody-drug conjugate moved earlier in the treatment sequence, including monotherapy for patients not candidates for PD-1/PD-L1 therapy and combination use with pembrolizumab for PD-L1 positive disease. The hook is earlier-line access, not cure.

Why now

The story reframes a cancer trial as an access problem: a patient could join because the trial reached her community instead of requiring long-distance care.

Why now

This is a rare good-news cancer story where the possible breakthrough is less treatment burden, not more intervention.

Why now

The story is about a specialized liver-directed chemotherapy path becoming available locally to a patient whose metastases were not surgically removable.